Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.58 |
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.56 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.54 |
| ▸ | FAAH | O00519 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15511925 | 0.89 | SLC2A1 (0.49) | SLC2A1GPR119CHEK2FAAHHDAC1 | |
| SCHEMBL15495662 | 0.89 | SLC2A1 (0.49) | SLC2A1GPR119CHEK2FAAHHDAC1 | |
| SCHEMBL391706 | 0.88 | GPR119 (0.71) | GPR119CHEK2FAAH | |
| SCHEMBL31540016 | 0.88 | GPR119 (0.54) | SLC2A1GPR119CHEK2FAAH | |
| SCHEMBL23693081 | 0.87 | GPR119 (0.48) | SLC2A1GPR119CHEK2 | |
| SCHEMBL3249170 | 0.87 | KDM4E (0.61) | SLC2A1GPR119CHEK2 | |
| SCHEMBL15412759 | 0.86 | GPR119 (0.58) | GPR119CHEK2HDAC1 | |
| SCHEMBL12834985 | 0.86 | GPR119 (0.58) | GPR119CHEK2HDAC1 | |
| SCHEMBL27158145 | 0.86 | CHEK2 (0.56) | SLC2A1GPR119CHEK2 | |
| SCHEMBL29716381 | 0.85 | GPR119 (0.55) | SLC2A1GPR119CHEK2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117715904-A | CDK2 degrading agents and uses thereof | 凯麦拉医疗公司 | 2024-03-15 | — | — | CN | disclosed |
| EP-4334307-A1 | CDK2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| WO-2022236058-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| US-20050143391-A1 | Heterocyclic amides with alpha-4 integrin antagonist activity | J. Uriach Y Compañia S.A. (ES) | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143391-A1 | Heterocyclic amides with alpha-4 integrin antagonist activity | ITGB4, ITGA4, ITGA1 | SLC2A1 3252/4885GPR119 789/4885CHEK2 3076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.